BCNA welcomes expanded access to vital metastatic breast cancer treatment on PBS 

Breast Cancer Network Australia (BCNA) welcomes the Australian Government’s announcement today that it will provide access to the life-prolonging drug Enhertu (trastuzumab deruxtecan) on the Pharmaceutical Benefits Scheme (PBS) from 1 September 2024. This change will have a profound impact on those diagnosed with HER2-low metastatic breast cancer. 

Enhertu comes from the group of targeted therapies for metastatic breast cancer, which focus specifically on cancer cells rather than affecting the whole body like traditional chemotherapy. This approach aims to minimise harm to healthy cells, potentially leading to fewer side effects and more effective treatment outcomes. By targeting specific markers on cancer cells, these therapies provide a more precise and personalised approach to treatment.

HER2-low is a recently identified subtype of breast cancer with lower levels of the HER2 protein than HER2-positive breast cancer. About 55% of people with breast cancer are estimated to have the HER2-low subtype. Before being added to the PBS, the drug cost between $10,000 and $15,000 every three weeks, putting it out of reach for most patients.

“Access to Enhertu on the PBS for HER2-low breast cancer marks a crucial milestone for Australians living with metastatic breast cancer,” said Vicki Durston, Director of Policy, Advocacy & Support Services for BCNA. “This listing is more than just an addition to the PBS; it provides hope for those, like Sarah, who desperately need it.”  

BCNA consumer, Sarah, who accessed Enhertu privately at a cost of over $200,000 also welcomes the decision:

“The financial burden of Enhertu drained my life savings, and the fear of what would happen when the money ran out was overwhelming. I'm deeply relieved that Enhertu is now on the PBS, ensuring that no one else has to endure the same financial and emotional strain that I did.” 

Media contact:  

Media and Communications Team
03 9805 2540
media@bcna.org.au